ACADIA Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ACAD and other ETFs, options, and stocks.

About ACAD

ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. 

CEO
Catherine Owen Adams
CEOCatherine Owen Adams
Employees
798
Employees798
Headquarters
San Diego, California
HeadquartersSan Diego, California
Founded
1993
Founded1993
Employees
798
Employees798

ACAD Key Statistics

Market cap
4.37B
Market cap4.37B
Price-Earnings ratio
11.94
Price-Earnings ratio11.94
Dividend yield
Dividend yield
Average volume
2.18M
Average volume2.18M
High today
$26.20
High today$26.20
Low today
$25.30
Low today$25.30
Open price
$26.04
Open price$26.04
Volume
1.54M
Volume1.54M
52 Week high
$28.35
52 Week high$28.35
52 Week low
$19.69
52 Week low$19.69

Stock Snapshot

The current ACADIA Pharmaceuticals(ACAD) stock price is $25.50, with a market capitalization of 4.37B. The stock trades at a price-to-earnings (P/E) ratio of 11.94.

On 2026-07-13, ACADIA Pharmaceuticals(ACAD) stock traded between a low of $25.30 and a high of $26.20. Shares are currently priced at $25.50, which is +0.8% above the low and -2.7% below the high.

ACADIA Pharmaceuticals(ACAD) shares are trading with a volume of 1.54M, against a daily average of 2.18M.

In the last year, ACADIA Pharmaceuticals(ACAD) shares hit a 52-week high of $28.35 and a 52-week low of $19.69.

In the last year, ACADIA Pharmaceuticals(ACAD) shares hit a 52-week high of $28.35 and a 52-week low of $19.69.

ACAD News

Nasdaq 2d
An Acadia Pharmaceuticals Insider Sold Nearly Half Their Shares in the Company. What Does That Mean for Investors?

Key Points Principal Accounting Officer James Kihara sold 11,421 shares for a transaction value of approximately ~$298,000 on June 26, 2026. The sale represen...

An Acadia Pharmaceuticals Insider Sold Nearly Half Their Shares in the Company. What Does That Mean for Investors?
Simply Wall St 3d
Is ACADIA Pharmaceuticals Undervalued On Rett Progress And Its Leadership Change?

Advertisement Executive change and recent Rett syndrome update put ACADIA Pharmaceuticals in focus ACADIA Pharmaceuticals (ACAD) has drawn fresh attention aft...

Is ACADIA Pharmaceuticals Undervalued On Rett Progress And Its Leadership Change?
Simply Wall St 5d
ACADIA Pharmaceuticals Stock Looks Undervalued After A 21% Run

ACADIA Pharmaceuticals stock has delivered a 20.5% return over the past year, yet on current checks it still screens as undervalued, which raises the question o...

ACADIA Pharmaceuticals Stock Looks Undervalued After A 21% Run

Analyst ratings

76%

of 21 ratings
Buy
76.2%
Hold
19%
Sell
4.8%

More ACAD News

TipRanks 7d
Acadia Pharmaceuticals price target raised to $36 from $29 at RBC Capital

RBC Capital analyst Brian Abrahams raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $36 from $29 and keeps an Outperform rating on the shares...

People also own

Based on the portfolios of people who own ACAD. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.